


**Objective:**

A phase III, randomised trial to determine whether the addition to neo-adjuvant chemotherapy of an anti-angiogenic agent bevacizumab is more effective than standard chemotherapy alone in terms of short-term and long-term outcome in women presenting with HER2-negative early breast cancer. Associated translational science will use prospective molecular profiling and candidate gene analysis on paraffin-embedded and fresh tissue to define molecular predictors of response/ resistance to bevacizumab and chemotherapy. Quality of life and health economics sub-studies will collect data critical to any future health technology assessment of bevacizumab in this indication.

**Trial Schema:**



**Contact Details:**

**Chief Investigators**

Dr Helena Earl  
*ARTemis Trial*  
Oncology Box 193 (R4)  
Hills Road  
Cambridge  
CB2 0QQ  
[hme22@cam.ac.uk](mailto:hme22@cam.ac.uk)

Dr. Larry Hayward  
[Larry.hayward@luht.scot.nhs.uk](mailto:Larry.hayward@luht.scot.nhs.uk)

**Trial Coordinators**

Anne-Laure Vallier  
*ARTemis Trial*  
Cambridge Cancer Trials Centre  
Box 279 (S4)  
Addenbrookes Hospital  
Hills Road  
Cambridge  
CB2 0QQ  
[Anne-laure.vallier@addenbrookes.nhs.uk](mailto:Anne-laure.vallier@addenbrookes.nhs.uk)

Louise Grybowicz  
*ARTemis Trial*  
Cambridge Cancer Trials Centre  
Box 279 (S4)  
Addenbrookes Hospital  
Hills Road  
Cambridge  
CB2 0QQ  
[Louise.grybowicz@addenbrookes.nhs.uk](mailto:Louise.grybowicz@addenbrookes.nhs.uk)  
Tel: 01223 348447

Clare Blenkinsop  
*ARTemis Trial*  
Warwick Clinical Trials Unit  
University of Warwick  
Gibbet Hill Road  
Coventry  
CV4 7AL  
[c.blenkinsop@warwick.ac.uk](mailto:c.blenkinsop@warwick.ac.uk)  
Tel: 024 7615 1057